##article.abstract##
<p>Objetivo. Estudiar y describir la relación entre la oclusión de la vena central de la retina y el glaucoma neovascular, su etiología, epidemiología, fisiopatología, factores de riesgo, presentación clínica y tratamientos. Metodología. Revisión de la literatura acerca del glaucoma neovascular secundario a oclusión de la vena central de la retina, tomando artículos comprendidos entre 2014 y 2022, con criterios de exclusión artículos de series de casos. Resultados. El glaucoma neovascular (GNV) es una afectación patológica ocular, secundaria a una afección ocular y/o sistémica hipóxica que conduce a isquemia retiniana, dentro de las etiologías más comunes (33 %) se encuentra la oclusión de la vena central de la retina (OVCR) una retinopatía vascular común que puede presentarse como isquémica o no isquémica. Discusión de resultados. La OVCR ocurre secundariamente a cambios estructurales glaucomatosos o coexiste con la anormalidad hemodinámica de la retina, esta es mediada por procesos inflamatorios como consecuencia de la isquemia retiniana y la hemorragia, lo cual aumenta la expresión de factor de crecimiento endotelial vascular (VEGF) y otros factores inflamatorios en el ojo, que pueden llevar a GNV. Conclusiones. El GNV es una patología con una presentación clínica severa, se asocia de forma directa con la OVCR y tiene múltiples opciones de tratamientos.</p>##submission.citations##
Nicholson L, Talks SJ, Amoaku W, Talks K, Sivaprasad S. Retinal vein occlusion (RVO) guideline: executive summary. Eye. 2022;36(5):909–12.
Scott IU, Campochiaro PA, Newman NJ, Biousse V. Retinal vascular occlusions. Lancet. 2020;396(10266):1927–40
Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein oc-clusion: A systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9(1).
Rong AJ, Swaminathan SS, Vanner EA, Parrish RK. Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. Am J Ophthalmol. 2019;204:62–9.
Yin X, Li J, Zhang B, Lu P. Association of glaucoma with risk of retinal vein occlu-sion A meta‐analysis. 2019
Casselholm de Salles M, Lindberg C, Epstein D. Neovascular glaucoma in patients with central retinal vein occlusion: A real-life study in the anti-VEGF era. Acta Op-hthalmol. 2021;99(1):e7–12
Sirisha Senthil, Tanuj Dada1, Taraprasad Das2, Sushmita Kaushik3, George Varghese Puthuran4 RP, Padmaja Kumari Rani2, Harsha Rao6, Shaveta Singla LV. Neovascular glaucoma - A review. Indian J Ophthalmol. 2021;69(525).
Gustavo B. Rodrigues, RYA, Zangalli1 C, Sodre1 SL, Donini1 FA, Costa1 DC, LEite1 A, et al. Neovascular glaucoma: A review. Int J Retin Vitr. 2016;2(1):1–10
Mishra C MJ. Glaucoma neovascular [Internet]. StatPearls. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK576393/?report=classic
Lilia Dumbrăveanu, Valeriu Cușnir DB. A review of neovascular glaucoma. Etiopa-thogenesis and treatment. JAMA. 2021;65(4)
Havens S, Gulati JV. Neovascular glaucoma. Dev Ophthalmol. 2016;55:196–204
AlRubaie K, Albahlal A, Alzahim T, Edward DP, Kozak I, Khandekar RB. Neo-vascular Glaucoma Progress and Impact of Therapeutic Intervention in Saudi Ara-bia. Cureus. 2021;13(9).
Yang H, Yu X, Sun X. Neovascular glaucoma: Handling in the future. Taiwan J Ophthalmol. 2018;8:53–5
Robert N. Weinreb, MD, Tin Aung, MD, PhD and FAM. The Pathophysiology and Treatment of Glaucoma: A Review. JAMA. 2014
Wiggs JL, Pasquale LR. Genetics of glaucoma. Hum Mol Genet. 2017;26(R1):R21–7.
Schuster AK, Erb C, Hoffmann EM, Dietlein T, Pfeiffer N. The diagnosis and treatment of glaucoma. Dtsch Arztebl Int. 2020;117(13):225–34.
Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer EM. Inflammation in Glaucoma: From the back to the front of the eye, and beyond. Prog Retin Eye Res. 2021;83.
Lee SS-Y, Mackey DA. Glaucoma – risk factors and current challenges in the diag-nosis of a leading cause of visual impairment. Maturitas. 2022;163:15–22
Dietze J, Blair K, Havens S. Glaucoma. StatPearls. 2022.
McMonnies CW. Glaucoma history and risk factors. J Optom [Internet]. 2017;10(2):71–8. Available from: http://dx.doi.org/10.1016/j.optom.2016.02.003
Trivli A, Zervou MI, Goulielmos GN, Spandidos DA, Detorakis ET. Primary open angle glaucoma genetics: The common variants and their clinical associations (Re-view). Mol Med Rep. 2020;22(2):1103–10
Sun X, Dai Y, Chen Y, Yu DY, Cringle SJ, Chen J, et al. Primary angle closure glaucoma: What we know and what we don’t know. Prog Retin Eye Res [Internet]. 2017;57:26–45. Available from: http://dx.doi.org/10.1016/j.preteyeres.2016.12.003
Khazaeni B, Khazaeni L. Acute Closed Angle Glaucoma [Internet]. StatPearls. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430857/
DeBoer C, Wong B, Ameri H. Ischemic index and distribution of retinal capillary non-perfusion in neovascular glaucoma. Front Biosci - Landmark. 2022;27(1):1–6.
Barac IR, Pop MD aniel., Gheorghe AI onu., Taban C. Neovascular Secondary Glaucoma, Etiology and Pathogenesis. Rom J Ophthalmol. 2015;59(1):24–8.
Tang Y, Cheng Y, Wang S, Wang Y, Liu P, Wu H. Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion. Front Med. 2022;9(June):1–18.
Kim YN, Shin JW, Park YJ, Lee JY, Kim JG, Yoon YH, et al. Glaucoma as a prog-nostic factor of central retinal vein occlusion: visual and anatomical outcomes and occurrence of ischaemic central retinal vein occlusion. Acta Ophthalmol. 2021;99(4):e523–30
Lee YH, Kim YC. Central retinal thickness changes and risk of neovascular glau-coma after intravitreal bevacizumab injection in patients with central retinal vein oc-clusion. Sci Rep [Internet]. 2022;12(1):1–6. Available from: https://doi.org/10.1038/s41598-022-06121-x
Acta Ophthalmologica - 2020 - Ducloyer - Predictive values of initial semi‐quantitative assessment of relative afferent pupillary defect for neovascularization in central retinal vein occlusion.pdf
Călugăru D, Călugăru M. Etiology, pathogenesis, and diagnosis of neovascular glaucoma. Int J Ophthalmol. 2022;15(6):1005–10
Woo SCY, Lip GYH, Lip PL. Associations of retinal artery occlusion and retinal vein occlusion to mortality, stroke, and myocardial infarction: A systematic review. Eye [Internet]. 2016;30(8):1031–8. Available from: http://dx.doi.org/10.1038/eye.2016.111
Chen HF, Chen MC, Lai CC, Yeung L, Wang NK, Chen HSL, et al. Neovascular glaucoma after central retinal vein occlusion in pre-existing glaucoma. BMC Op-hthalmol. 2014;14(1):1–6.
Noma H, Yasuda K, Shimura M. Cytokines and pathogenesis of central retinal Vein occlusion. J Clin Med. 2020;9(11):1–16.
Noma H, Yasuda K, Shimura M. Cytokines and the Pathogenesis of Macular Ede-ma in Branch Retinal Vein Occlusion. J Ophthalmol. 2019;2019
Ehlken C, Grundel B, Michels D, Junker B, Stahl A, Schlunck G, et al. Increased expression of angiogenic and inflammatory proteins in the vitreous of patients with ischemic central retinal vein occlusion. PLoS One. 2015;10(5):1–15.
Călugăru D, Călugăru M. Intraocular pressure modifications in patients with acute central/hemicentral retinal vein occlusions. Int J Ophthalmol. 2021;14(6):931–5.
Bradshaw SE, Gala S, Nanavaty M, Shah A, Mwamburi M, Kefalas P. Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion. BMC Ophthalmol [Internet]. 2016;16(1). Available from: http://dx.doi.org/10.1186/s12886-016-0282-5
Li C, Wang R, Liu G, Ge Z, Jin D, Ma Y, et al. Efficacy of panretinal laser in is-chemic central retinal vein occlusion: A systematic review. Exp Ther Med. 2018;(8):901–10.
Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tada-yoni R, et al. Guidelines for the Management of Retinal Vein Occlusion by the Eu-ropean Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242(3):123–62.
Nagasato D, Muraoka Y, Osaka R, Iida-Miwa Y, Mitamura Y, Tabuchi H, et al. Factors associated with extremely poor visual outcomes in patients with central reti-nal vein occlusion. Sci Rep [Internet]. 2020;10(1):1–8. Available from: https://doi.org/10.1038/s41598-020-76840-6
Ghanchi F, Bourne R, Downes SM, Gale R, Rennie C, Tapply I, et al. An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior seg-ment: AMD, DMO, RVO, uveitis and glaucoma. Eye. 2022;36(6):1154–67
Formica ML, Awde Alfonso HG, Palma SD. Biological drug therapy for ocular an-giogenesis: Anti-VEGF agents and novel strategies based on nanotechnology. Pharmacol Res Perspect. 2021;9(2):1–18.
He S, Stankowska DL, Ellis DZ, Krishnamoorthy RR, Yorio T. Targets of neuropro-tection in glaucoma. J Ocul Pharmacol Ther. 2018;34(1–2):85–106
Senthil S, Chary R, Ali MH, Cherukuri JR, Rani PK, Krishnamurthy R, et al. Tra-beculectomy for neovascular glaucoma in proliferative diabetic retinopathy, central retinal vein occlusion, and ocular ischemic syndrome: Surgical outcomes and prog-nostic factors for failure. BMC Ophthalmol [Internet]. 2021;69(3341–8):1. Availa-ble from: http://www.ncbi.nlm.nih.gov/pubmed/28331284%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5354527%5Cnhttp://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-11-49%5Cnhttp://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886
Kang YK, Shin JP, Kim DW. Long-term surgical outcomes of Ahmed valve implan-tation in refractory glaucoma according to the type of glaucoma. BMC Ophthalmol [Internet]. 2022;22(1):1–9. Available from: https://doi.org/10.1186/s12886-022-02493-w
Gillmann K, Mansouri K. Minimally invasive glaucoma surgery: Where is the evi-dence? Asia-Pacific J Ophthalmol. 2020;9(3):203–14.
Michelessi M, Bicket AK, Lindsley K. Cyclodestructive procedures for non-refractory glaucoma. Cochrane Database Syst Rev. 2018;2018(4).
Chen ZN, Shao Y, Li XR. Radial optic neurotomy in treating central retinal vein oc-clusion: A Meta-analysis. Int J Ophthalmol. 2016;9(6):898–903.
Lorenz K, Scheller Y, Bell K, Grus F, Ponto KA, Bock F, et al. A prospective, ran-domised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlu-sion to Prevent Neovascular Glaucoma - the STRONG study: Study protocol f. Tri-als. 2017;18(1):1–12.
Hu XN, Ni Y, Luan J, Ding YZ. A review on vasohibin and ocular neovasculariza-tion. Int J Ophthalmol. 2020;13(6):1004–8
